Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink

Leerink affirms Sarepta (Nasdaq: SRPT) at Underperform with a price target of $5 after the company announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA).

Analyst Joseph P. Schwartz commented, [Sarepta's] PR disclosing the imminent submission of biopsy samples (n=13; baseline and week 48) re-ignited optimism for eteplirsen. In light of the FDA/AdCom's lack of enthusiasm for previous dystrophin data, its lack of correlation with functional outcomes, and numerous other questionable factors, we detail four reasons to remain cautious. Although the market's initial knee-jerk reaction is positive (~25%+ in after-hours), with today's disclosure providing minimal detail suggesting a change in course is likely we are reiterating our UP rating on SRPT.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

You May Also Be Interested In

• FDA accepts Sarepta's applications to convert two DMD drugs to full approval
• H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
• JPMorgan Downgrades SIMPAR SA (SIMH3:BZ) to Neutral